25 results on '"Naik, Snehal"'
Search Results
2. Challenges and Opportunities in IBD Clinical Trial Design
3. The functional repertoire of rabbit antibodies and antibody discovery via next-generation sequencing
4. Real-time imaging of [beta]-catenin dynamics in cells and living mice
5. Su1926 FECAL CALPROTECTIN AND C-REACTIVE PROTEIN LEVELS ARE CORRELATED WITH LONG TERM CLINICAL AND ENDOSCOPIC OUTCOMES: ANALYSIS OF THE OASIS OPEN LABEL EXTENSION TRIAL OF ETRASIMOD FOR ULCERATIVE COLITIS
6. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis
7. 1006 – Histologic Remission and Mucosal Healing in a Randomized, Placebo-Controlled, Phase 2 Study of Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis
8. Tu1745 – Correlation of Fecal Calprotectin and C-Reactive Protein Concentrations with Clinical Outcomes and Endoscopic Disease Activity in Patients with Ulcerative Colitis Receiving Induction Therapy with Etrasimod
9. 233 - Low Infliximab Levels and Anti-Infliximab Antibodies Increase the Risk of Loss of Response to Infliximab in Pediatric IBD, a Prospective Pediatric Study
10. Mo1857 - Vedolizumab Levels During Induction are Associated with Long-Term Clinical and Endoscopic Remission in Patients with Inflammatory Bowel Disease
11. Higher Vedolizumab Trough Levels Associated with Remission in Inflammatory Bowel Disease (IBD) During Maintenance Therapy
12. Higher Vedolizumab Levels are Associated with Deep Remission in Patients with Crohn's Disease and Ulcerative Colitis on Maintenance Therapy with Vedolizumab
13. RNA Interference Screen Identifies VEGFR1 as Potentially Synthetic Lethal to Aberrant Wnt/β-catenin Activation in Colon Cancer
14. Sa1906 - Higher Vedolizumab Levels are Associated with Deep Remission in Patients with Crohn's Disease and Ulcerative Colitis on Maintenance Therapy with Vedolizumab
15. Sa1891 - Higher Vedolizumab Trough Levels Associated with Remission in Inflammatory Bowel Disease (IBD) During Maintenance Therapy
16. Establishment of paternal allele-specific DNA methylation at the imprinted mouseGtl2locus
17. Peroxisome Proliferator-Activated Receptor-α Activation Promotes Macrophage Reverse Cholesterol Transport Through a Liver X Receptor–Dependent Pathway
18. Dual-Color Click Beetle Luciferase Heteroprotein Fragment Complementation Assays
19. Abstract LB-137: Reversibility of click beetle luciferase heteroprotein fragment complementation systems for imaging cancer pathways in live cells
20. Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant β-Catenin Activation in Colon Cancer
21. Both the Peroxisome Proliferator-Activated Receptor δ Agonist, GW0742, and Ezetimibe Promote Reverse Cholesterol Transport in Mice by Reducing Intestinal Reabsorption of HDL-Derived Cholesterol
22. Pharmacological Activation of Liver X Receptors Promotes Reverse Cholesterol Transport In Vivo
23. Regulation of Cysteinyl Leukotriene Type 1 Receptor Internalization and Signaling
24. Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant {beta}-Catenin Activation in Colon Cancer.
25. Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.